BDSI

BioDelivery Sciences InternationalNasdaqGS:BDSI Stock Report

Market Cap

US$393.4m

7D

-6.8%

1Y

-2.0%

Updated

18 Sep, 2021

Data

Company Financials +
BDSI fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance6/6
Financial Health5/6
Dividends0/6

BDSI Overview

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally.

BioDelivery Sciences International Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BioDelivery Sciences International
Historical stock prices
Current Share PriceUS$3.99
52 Week HighUS$3.04
52 Week LowUS$4.99
Beta0.70
1 Month Change16.33%
3 Month Change9.62%
1 Year Change-1.97%
3 Year Change40.00%
5 Year Change47.78%
Change since IPO20.91%

Recent News & Updates

Sep 09

BioDelivery Sciences: Legal Fees Are Causing My Pain

Share price performance has been a massive disappointment since I last covered the stock. I provide my updated valuation of BDSI to represent the acquisition of US and Canadian rights to ELYXYB. My model shows shares are trading at a discount of ~67%. Litigation costs and risks are mounting and seem to be the main culprit for the discount to fair value.

Aug 27

BioDelivery Sciences: Yet Another Buying Opportunity

BDSI trades at extremely low P/E and EV/S ratios for a company that is still growing at a good clip. Management has cleared up a few concerns by finally starting the process of buying back shares and stopping the dilution that happened for so long. The largest risk remains ongoing litigation with AQST.

Aug 27
Does BioDelivery Sciences International (NASDAQ:BDSI) Deserve A Spot On Your Watchlist?

Does BioDelivery Sciences International (NASDAQ:BDSI) Deserve A Spot On Your Watchlist?

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

Shareholder Returns

BDSIUS PharmaceuticalsUS Market
7D-6.8%-2.5%-0.6%
1Y-2.0%11.0%33.8%

Return vs Industry: BDSI underperformed the US Pharmaceuticals industry which returned 11% over the past year.

Return vs Market: BDSI underperformed the US Market which returned 33.8% over the past year.

Price Volatility

Is BDSI's price volatile compared to industry and market?
BDSI volatility
BDSI Beta0.70
Industry Beta0.64
Market Beta1

Stable Share Price: BDSI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: BDSI's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997176Jeff Baileyhttps://www.bdsi.com

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients.

Valuation

Is BioDelivery Sciences International undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BDSI ($3.99) is trading below our estimate of fair value ($33.06)

Significantly Below Fair Value: BDSI is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BDSI is good value based on its PE Ratio (11.6x) compared to the US Pharmaceuticals industry average (22.9x).

PE vs Market: BDSI is good value based on its PE Ratio (11.6x) compared to the US market (17.8x).


Price to Earnings Growth Ratio

PEG Ratio: BDSI is good value based on its PEG Ratio (0.3x)


Price to Book Ratio

PB vs Industry: BDSI is overvalued based on its PB Ratio (3.5x) compared to the US Pharmaceuticals industry average (3.3x).


Future Growth

How is BioDelivery Sciences International forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

39.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BDSI's forecast earnings growth (39% per year) is above the savings rate (2%).

Earnings vs Market: BDSI's earnings (39% per year) are forecast to grow faster than the US market (14.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BDSI's revenue (18.2% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: BDSI's revenue (18.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BDSI's Return on Equity is forecast to be high in 3 years time


Past Performance

How has BioDelivery Sciences International performed over the past 5 years?

41.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BDSI has high quality earnings.

Growing Profit Margin: BDSI's current net profit margins (20.7%) are higher than last year (4.2%).


Past Earnings Growth Analysis

Earnings Trend: BDSI has become profitable over the past 5 years, growing earnings by 41% per year.

Accelerating Growth: BDSI's earnings growth over the past year (485.3%) exceeds its 5-year average (41% per year).

Earnings vs Industry: BDSI earnings growth over the past year (485.3%) exceeded the Pharmaceuticals industry 17.5%.


Return on Equity

High ROE: BDSI's Return on Equity (29.7%) is considered high.


Financial Health

How is BioDelivery Sciences International's financial position?


Financial Position Analysis

Short Term Liabilities: BDSI's short term assets ($196.1M) exceed its short term liabilities ($63.9M).

Long Term Liabilities: BDSI's short term assets ($196.1M) exceed its long term liabilities ($72.5M).


Debt to Equity History and Analysis

Debt Level: BDSI's debt to equity ratio (69%) is considered high.

Reducing Debt: BDSI's debt to equity ratio has reduced from 445.2% to 69% over the past 5 years.

Debt Coverage: BDSI's debt is well covered by operating cash flow (51.3%).

Interest Coverage: BDSI's interest payments on its debt are well covered by EBIT (5.3x coverage).


Balance Sheet


Dividend

What is BioDelivery Sciences International current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BDSI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BDSI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BDSI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BDSI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BDSI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Jeff Bailey (58 yo)

1.33yrs

Tenure

US$3,953,210

Compensation

Mr. Jeffrey Allen Bailey, also known as Jeff, has been Chief Executive Officer at BioDelivery Sciences International, Inc. since November 4, 2020. Mr. Bailey served as Interim Chief Executive Officer at Bi...


CEO Compensation Analysis

Compensation vs Market: Jeff's total compensation ($USD3.95M) is above average for companies of similar size in the US market ($USD1.67M).

Compensation vs Earnings: Insufficient data to compare Jeff's compensation with company performance.


Leadership Team

Experienced Management: BDSI's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: BDSI's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

BioDelivery Sciences International, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: BioDelivery Sciences International, Inc.
  • Ticker: BDSI
  • Exchange: NasdaqGS
  • Founded: 1997
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$393.404m
  • Shares outstanding: 98.60m
  • Website: https://www.bdsi.com

Number of Employees


Location

  • BioDelivery Sciences International, Inc.
  • 4131 ParkLake Avenue
  • Suite 225
  • Raleigh
  • North Carolina
  • 27612
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/18 22:16
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.